2016
DOI: 10.1007/s00417-016-3284-3
|View full text |Cite
|
Sign up to set email alerts
|

A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2018
2018
2018
2018

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 6 publications
0
1
0
Order By: Relevance
“… 8 18 Other anti-VEGF agents such as aflibercept (Eylea; Regeneron Pharmaceuticals, Inc, Tarrytown, NY) are also approved for these conditions, whereas only off-label use of bevacizumab (Avastin; Genentech, Inc) has been reported. 19 28 …”
mentioning
confidence: 99%
“… 8 18 Other anti-VEGF agents such as aflibercept (Eylea; Regeneron Pharmaceuticals, Inc, Tarrytown, NY) are also approved for these conditions, whereas only off-label use of bevacizumab (Avastin; Genentech, Inc) has been reported. 19 28 …”
mentioning
confidence: 99%